Jubilant Cadista Pharmaceuticals, Inc. has voluntarily recalled 23,616 blister packs of Olanzapine Orally Disintegrating Tablets (5 mg), a prescription medication used to treat certain mental health conditions. The recall was initiated because the tablets were found to be subpotent, meaning they may not contain the full required amount of the active ingredient. This medication was distributed nationwide in 30-count blister packs (3x10 unit doses). If you have this medication, you should contact your healthcare provider or pharmacist for guidance regarding your treatment.
The tablets are subpotent, which means they do not meet the required strength specifications. This could result in a patient receiving a lower dose of medication than intended, potentially leading to a lack of effectiveness in managing their medical condition.
Healthcare provider consultation and pharmacy refund.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.